title: Absence of complement-mediated events after protamine reversal of heparin anticoagulation.
abstract: Protamine reversal of heparin anticoagulation is associated with adverse hemodynamic effects that may be attenuated with protamine pretreatment (PP). This study assesses the role of complement activation during these phenomena in adult cardiac surgery patients. Sixteen individuals undergoing cardiopulmonary bypass were given intravenous normal saline or protamine (2 mg/kg) as a randomized pretreatment prior to undergoing heparin anticoagulation (400 IU/kg), coronary artery revascularization, and subsequent reversal of the anticoagulated state with protamine (4 mg/kg). Blood pressure, pulmonary artery diastolic pressure (PAD), heart rate, and cardiac output (CO) were measured during and after pretreatment, prior to heparin reversal by protamine, and for 10 min after reversal. Total hemolytic complement (CH50), C3 conversion to C3b, C3a/C5a, platelet count, and white blood cell count (WBC) were also measured at the same time periods. No significant correlation existed between complement activation and hemodynamic events, as might have been evident by decreased CH50, increased C3 conversion to C3b, or elevations in C3a/C5a levels. PP significantly prevented the CO decrease occurring at 1 and 3 min following heparin reversal by protamine (-0.8 and -1.4 liters/min vs 0.1 and -0.2 liters/min, P less than 0.05 and P less than 0.01, respectively). Reversal hypotension was less with PP, although PAD fell equally in both groups. WBC decreases after heparin reversal were less after PP (-25% vs -7%, P = 0.06). These data support the conclusion that, contrary to earlier reports, adverse hemodynamic and hematologic responses accompanying protamine reversal of heparin anticoagulation do not appear to be correlated with activation of complement. In fact, those patients having the greatest C3a generation exhibited the least hemodynamic changes.
authors.affiliation: Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109.
authors.forename: T W
authors.initials: TW
authors.lastname: Wakefield
authors.forename: M M
authors.initials: MM
authors.lastname: Kirsh
authors.forename: G O
authors.initials: GO
authors.lastname: Till
authors.forename: T E
authors.initials: TE
authors.lastname: Brothers
authors.forename: C B
authors.initials: CB
authors.lastname: Hantler
authors.forename: J C
authors.initials: JC
authors.lastname: Stanley
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000037:antagonists & inhibitors*; D002302:Cardiac Output / Q000187:drug effects; D002315:Cardiopulmonary Bypass; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D003179:Complement C3b / Q000378:metabolism; D003165:Complement System Proteins / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects; D006494:Heparin Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011479:Protamines / Q000494:pharmacology*
chemical_list: D000925:Anticoagulants; D003176:Complement C3; D006494:Heparin Antagonists; D011479:Protamines; D003179:Complement C3b; D003165:Complement System Proteins